The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy

Cell surface molecules of the B7/CD28 family play an important role in T-cell activation and tolerance. The relevance of the PD-1/PD-L1 pathway in cancer has been extensively studied whereas PD-L2 has received less attention. However, recently the expression of PD-L2 was described to be independentl...

Full description

Bibliographic Details
Main Authors: Shamaila Munir Ahmad, Evelina Martinenaite, Morten Holmström, Mia Aaboe Jørgensen, Özcan Met, Claudia Nastasi, Uffe Klausen, Marco Donia, Lars Møller Pedersen, Lars Munksgaard, Niels Ødum, Anders Woetmann, Inge Marie Svane, Mads Hald Andersen
Format: Article
Language:English
Published: Taylor & Francis Group 2018-02-01
Series:OncoImmunology
Subjects:
anti-cancer immunity
cd4+ t cells
cd8+ t cells
immune checkpoint regulator
pd-l2
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1390641

Internet

http://dx.doi.org/10.1080/2162402X.2017.1390641

Similar Items